Literature DB >> 3079639

Incorporation and degradation of GM1 ganglioside and asialoGM1 ganglioside in cultured fibroblasts from normal individuals and patients with beta-galactosidase deficiency.

T Kobayashi, N Shinnoh, Y Kuroiwa.   

Abstract

The uptake and degradation of GM1 ganglioside (GM1) and asialoGM1 ganglioside (GA1) were studied in cultured fibroblasts from normal individuals and patients with beta-galactosidase deficiency, using the lipid-loading test. The glycolipids were incorporated from the media into the fibroblasts and the terminal galactose was hydrolyzed in normal cells. The hydrolysis rates of GA1 were 80-86% of normal on the 3rd day after loading, while GM1 was hydrolyzed slowly; 35-54% on the 14th day. In infantile GM1 gangliosidosis and I-cell disease, little GM1 and GA1 was hydrolyzed on any day of culture, while fibroblasts from patients with adult GM1 gangliosidosis, Morquio disease type B and galactosialidosis hydrolyzed the lipids at nearly normal rates. The intracellular accumulation of the glycolipids, on the basis of protein content, was abnormally high in the case of infantile GM1 gangliosidosis and I-cell disease, but normal in the other disorders examined. These observations indicate that the in situ metabolism of GM1 and GA1 is probably normal in fibroblasts from patients with adult GM1 gangliosidosis, Morquio disease type B and galactosialidosis, although in vitro beta-galactosidase activities in these disorders are very low. The results are compatible with findings that GM1 and GA1 do not accumulate in the somatic organs of patients with adult GM1 gangliosidosis and galactosialidosis. In I-cell disease, however, the results of the loading test did not agree with the finding that there is little accumulation of glycolipids in postmortem tissues.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3079639

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  Metabolism of GM1 ganglioside in cultured skin fibroblasts: anomalies in gangliosidoses, sialidoses, and sphingolipid activator protein (SAP, saposin) 1 and prosaposin deficient disorders.

Authors:  B Schmid; B C Paton; K Sandhoff; K Harzer
Journal:  Hum Genet       Date:  1992-07       Impact factor: 4.132

2.  Uptake and metabolism of radiolabelled GM1-ganglioside in skin fibroblasts from controls and patients with GM1-gangliosidosis.

Authors:  M Midorikawa; K Inui; S Okada; H Yabuuchi; K Ogura; S Handa
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

3.  Intracellular processing and maturation of mutant gene products in hereditary beta-galactosidase deficiency (beta-galactosidosis).

Authors:  A Oshima; K Yoshida; K Itoh; R Kase; H Sakuraba; Y Suzuki
Journal:  Hum Genet       Date:  1994-02       Impact factor: 4.132

4.  Intracerebroventricular enzyme replacement therapy with β-galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice.

Authors:  Joseph C Chen; Amanda R Luu; Nathan Wise; Rolando De Angelis; Vishal Agrawal; Linley Mangini; Jon Vincelette; Britta Handyside; Harry Sterling; Melanie J Lo; Hio Wong; Nicole Galicia; Glenn Pacheco; Jeremy Van Vleet; Alexander Giaramita; Sylvia Fong; Sushmita M Roy; Chuck Hague; Roger Lawrence; Sherry Bullens; Terri M Christianson; Alessandra d'Azzo; Brett E Crawford; Stuart Bunting; Jonathan H LeBowitz; Gouri Yogalingam
Journal:  J Biol Chem       Date:  2019-09-03       Impact factor: 5.157

Review 5.  Patient-Focused Selection of PrEP Medication for Individuals at Risk of HIV: A Narrative Review.

Authors:  Sheldon D Fields; Elyse Tung
Journal:  Infect Dis Ther       Date:  2021-02-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.